1. Anti-infection Stem Cell/Wnt Autophagy Apoptosis
  2. Bacterial Wnt β-catenin Mitophagy Autophagy Apoptosis Antibiotic Parasite
  3. Salinomycin

Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells.

For research use only. We do not sell to patients.

Salinomycin Chemical Structure

Salinomycin Chemical Structure

CAS No. : 53003-10-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 36 publication(s) in Google Scholar

Other Forms of Salinomycin:

Top Publications Citing Use of Products

33 Publications Citing Use of MCE Salinomycin

WB

    Salinomycin purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2021 Aug 4;11(1):156.  [Abstract]

    Salinomycin (0.0078125 μg/ml; for 24 h) reverses the MDLS-induced up-regulation of Oct4. The expression of Oct4 is determined using Western blot analysis.

    Salinomycin purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2018 Nov 23;16(1):89.  [Abstract]

    The expression of collagen I, α-smooth muscle actin (α-SMA), and Sca-1 in lung tissues is measured by western blotting in the treatment of Saline, Salinomycin, Bleomycin+Vehicle, and Bleomycin+ Salinomycin.

    Salinomycin purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Aug;40(2):877-886.  [Abstract]

    Salinomycin (SAL) has a pro-apoptotic effect on NB4 and HL-60 cells. The apoptosis-related protein levels of Bax and Bcl-2 are assessed by western blotting with the β-actin protein as an internal control.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells[1][2][3].

    IC50 & Target

    Coccidia

     

    Cellular Effect
    Cell Line Type Value Description References
    2008 IC50
    3.2 μM
    Compound: Salinomycin
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 28651817]
    2008 IC50
    4.78 μM
    Compound: Salinomycin
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 28651817]
    2008 IC50
    7.44 μM
    Compound: Salinomycin
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28651817]
    4T1 IC50
    3.78 μM
    Compound: 1
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    4T1 IC50
    3.78 μM
    Compound: 1; SAL
    Antiproliferative activity against mouse 4T1 cells by MTT assay
    Antiproliferative activity against mouse 4T1 cells by MTT assay
    [PMID: 30684870]
    A549 IC50
    3.98 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    A549 IC50
    3.98 μM
    Compound: 1; SAL
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    [PMID: 30684870]
    BALB/3T3 IC50
    27.76 μM
    Compound: SAL
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    [PMID: 26163197]
    BALB/3T3 IC50
    28.08 μM
    Compound: 1
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    [PMID: 23079523]
    BALB/3T3 IC50
    9.33 μM
    Compound: SAL
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    [PMID: 25644674]
    BEAS-2B IC50
    13.07 μM
    Compound: 1
    Cytotoxicity against human BEAS2B cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human BEAS2B cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    BT-474 CC50
    14 μM
    Compound: Salinomycin
    Cytotoxicity against human BT474 cells after 48 hrs by MTS assay
    Cytotoxicity against human BT474 cells after 48 hrs by MTS assay
    10.1039/C6MD00328A
    Caco-2 IC50
    12.99 μM
    Compound: 1; SAL
    Antiproliferative activity against human Caco2 cells by MTT assay
    Antiproliferative activity against human Caco2 cells by MTT assay
    [PMID: 30684870]
    DU-145 CC50
    > 20 μM
    Compound: Salinomycin
    Cytotoxicity against human DU145 cells after 48 hrs by MTS assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTS assay
    10.1039/C6MD00328A
    HEK293 IC50
    195 nM
    Compound: 1
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 29466777]
    HEK293 IC50
    329.5 nM
    Compound: 1
    Cytotoxicity against doxycycline inducible T-Rex/K-Ras G12V HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against doxycycline inducible T-Rex/K-Ras G12V HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 29466777]
    HeLa IC50
    0.32 μM
    Compound: 1; SAL
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    [PMID: 30684870]
    HeLa IC50
    4.49 μM
    Compound: 1
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    HepG2 IC50
    24.5 μM
    Compound: Salinomycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 30871771]
    HGC-27 IC50
    2.57 μM
    Compound: Sal
    Cytotoxicity against human HGC27 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HGC27 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    [PMID: 28262526]
    HGC-27 IC50
    2.57 μM
    Compound: 1; SAL
    Antiproliferative activity against human HGC27 cells by MTT assay
    Antiproliferative activity against human HGC27 cells by MTT assay
    [PMID: 30684870]
    HGC-27 IC50
    8.18 μM
    Compound: 1; SAL
    Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay
    [PMID: 30684870]
    HL-60 IC50
    0.29 μM
    Compound: SAL
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25644674]
    HL-60 IC50
    0.44 μM
    Compound: 1
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
    [PMID: 23079523]
    HL-60 IC50
    0.58 μM
    Compound: 1
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    HL-60 GI50
    50.5 μM
    Compound: SAL
    Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay
    Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay
    [PMID: 33071053]
    HL-60 GI50
    6.63 μM
    Compound: 1; SAL
    Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay
    Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay
    [PMID: 30986574]
    HT-29 IC50
    1.03 μM
    Compound: 1; SAL
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    [PMID: 30684870]
    HT-29 IC50
    1.03 μM
    Compound: SAL
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method
    [PMID: 25644674]
    HT-29 IC50
    1.43 μM
    Compound: 1; SAL
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    [PMID: 28688275]
    HT-29 IC50
    1.43 μM
    Compound: Sal
    Cytotoxicity against human HT-29 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    [PMID: 28262526]
    HT-29 IC50
    3.21 μM
    Compound: 1; SAL
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    [PMID: 30684870]
    JIMT-1 IC50
    0.52 μM
    Compound: 1
    Cytotoxicity against human JIMT1 cells after 72 hrs by MTT assay
    Cytotoxicity against human JIMT1 cells after 72 hrs by MTT assay
    [PMID: 27326340]
    JIMT-1 IC50
    0.52 μM
    Compound: 1; SAL
    Antiproliferative activity against human JIMT1 cells by MTT assay
    Antiproliferative activity against human JIMT1 cells by MTT assay
    [PMID: 30684870]
    JIMT-1 IC50
    1.3 μM
    Compound: 1; SAL
    Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay
    Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay
    [PMID: 30025346]
    JIMT-1 IC50
    1.3 μM
    Compound: 1; SAL
    Antiproliferative activity against human JIMT1 cells by SRB assay
    Antiproliferative activity against human JIMT1 cells by SRB assay
    [PMID: 30684870]
    LoVo IC50
    0.36 μM
    Compound: SAL
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method
    [PMID: 25644674]
    LoVo IC50
    0.44 μM
    Compound: 1; SAL
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay
    [PMID: 30025346]
    LoVo IC50
    0.44 μM
    Compound: 1; SAL
    Antiproliferative activity against human LoVo cells by SRB assay
    Antiproliferative activity against human LoVo cells by SRB assay
    [PMID: 30684870]
    LoVo IC50
    0.53 μM
    Compound: SAL
    Antiproliferative activity against human LoVo cells after 72 hrs
    Antiproliferative activity against human LoVo cells after 72 hrs
    [PMID: 26163197]
    LoVo IC50
    1.11 μM
    Compound: 1
    Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay
    [PMID: 23079523]
    LS180 IC50
    0.61 μM
    Compound: SAL
    Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method
    [PMID: 25644674]
    MCF-10A IC50
    46 μM
    Compound: 1; SAL
    Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay
    [PMID: 30025346]
    MCF-10A IC50
    46 μM
    Compound: 1; SAL
    Antiproliferative activity against human MCF10A cells by SRB assay
    Antiproliferative activity against human MCF10A cells by SRB assay
    [PMID: 30684870]
    MCF7 IC50
    0.59 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 27326340]
    MCF7 IC50
    0.59 μM
    Compound: 1; SAL
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    [PMID: 30684870]
    MCF7 IC50
    1.5 μM
    Compound: 1; SAL
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    [PMID: 30025346]
    MCF7 IC50
    1.5 μM
    Compound: 1; SAL
    Antiproliferative activity against human MCF7 cells by SRB assay
    Antiproliferative activity against human MCF7 cells by SRB assay
    [PMID: 30684870]
    MCF7 IC50
    2.98 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 27876192]
    MCF7 IC50
    9.08 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    MDA-MB-231 IC50
    > 10 μM
    Compound: 1; SAL
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 30684870]
    MDA-MB-231 CC50
    > 20 μM
    Compound: Salinomycin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay
    10.1039/C6MD00328A
    MDA-MB-231 IC50
    0.5 μM
    Compound: 30
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay
    [PMID: 33650861]
    MDA-MB-231 IC50
    6.42 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 27876192]
    MDA-MB-231 IC50
    6.42 μM
    Compound: 1; SAL
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells by SRB assay
    [PMID: 30684870]
    MDA-MB-231 IC50
    6.53 μM
    Compound: Sal
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    [PMID: 28262526]
    MDA-MB-231 IC50
    6.91 μM
    Compound: 1; SAL
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    [PMID: 30684870]
    MIA PaCa-2 CC50
    6.5 μM
    Compound: Salinomycin
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTS assay
    Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTS assay
    10.1039/C6MD00328A
    MV4-11 IC50
    0.33 μM
    Compound: SAL
    Antiproliferative activity against human MV4-11 cells after 72 hrs
    Antiproliferative activity against human MV4-11 cells after 72 hrs
    [PMID: 26163197]
    PC-3 EC50
    > 1 μM
    Compound: Salinomycin
    Antiproliferative activity against human PC3 cells after 48 hrs
    Antiproliferative activity against human PC3 cells after 48 hrs
    [PMID: 23063400]
    SK-BR-3 IC50
    0.89 μM
    Compound: 1; SAL
    Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay
    [PMID: 30025346]
    SK-BR-3 IC50
    0.89 μM
    Compound: 1; SAL
    Antiproliferative activity against human SKBR3 cells by SRB assay
    Antiproliferative activity against human SKBR3 cells by SRB assay
    [PMID: 30684870]
    SMMC-7721 IC50
    12.04 μM
    Compound: 1
    Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    SW480 IC50
    3.77 μM
    Compound: 1
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 48 hrs by MTS assay
    [PMID: 29466777]
    U-87MG ATCC IC50
    38.7 μM
    Compound: 1; SAL
    Antiproliferative activity against human U87 cells by MTT assay
    Antiproliferative activity against human U87 cells by MTT assay
    [PMID: 30684870]
    Vero CC50
    > 50 μM
    Compound: Salinomycin
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    10.1101/2020.03.20.999730
    Vero IC50
    0.24 μM
    Compound: Salinomycin
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    10.1101/2020.03.20.999730
    In Vitro

    Salinomycin is a potent inhibitor of the Wnt signaling cascade. Incubation of the malignant lymphocytes with Salinomycin induces apoptosis within 48 h, with a mean IC50 of 230 nM. Salinomycin is also an antibiotic potassium ionophore, has been reported recently to act as a selective breast cancer stem cell inhibitor[1].
    Salinomycin is a novel and an effective anticancer drug, inhibits SW620 cells and Cisp-resistant SW620 cells with IC50 of 1.54±0.23 μM and 0.32±0.05 μM, respectively. Salinomycin is found to have the ability to kill both cancer stem cells (CSCs) and therapy-resistant cancer cells. After continuous Salinomycin treatment for 48 h, the apoptotic cells are observed under the microscope and counted randomly at least 100 cells in one field. The number of apoptotic cells which are stained by Hoechst33342 is significantly increased in Cisp-resistant SW620 cells (20.20±3.72) than that of SW620 cells (9.40±2.07) per 100 cells (p<0.05). After treatment with Salinomycin for 48 h, flow cytometric analysis is used to detect the cell apoptosis both in SW620 cells and Cisp-resistant SW620 cells. The cell apoptotic rate in Cisp-resistant SW620 cells (37.82±3.63%) is significantly higher than that of SW620 cells (16.78±2.56%) (p<0.05)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    After administration of 4 mg/kg Salinomycin (Sal), 8 mg/kg Salinomycin and 10 uL/g saline water for 6 weeks, the mice are sacrificed. The size of the liver tumors in the Salinomycin treatment groups diminishes compare with the control group. The mean diameter of the tumors decreases from 12.17 mm to 3.67 mm (p<0.05) and the mean volume (V=length×width2×0.5) of the tumors decreases from 819 mm3 to 25.25 mm3 (p<0.05). Next, the tumors are harvested, followed by HE staining, immunohistochemistry, and TUNEL assays, to assess the anti-tumor activity of Salinomycin. HE staining shows that the structure of the liver cancer tissue:nuclei of different sizes, hepatic cord structure is destroyed. Immunohistochemistry shows that PCNA expression is lower after Salinomycin treatment. HE staining and TUNEL assays indicates the Salinomycin-treated groups has higher apoptosis rates than control. Furthermore, immunohistochemistry shows an increased Bax/Bcl-2 ratio after Salinomycin treatment. The protein expression of β-catenin decreases in the Salinomycin treatment groups compared with control[4].
    Salinomycin is a kind of monocarboxylic acid polyether type antibiotics, produced by the fermentation of Streptomyces albus, possesses a specific cyclic structure, and can form a complex compound with the pathogenic microorganisms and the extracellular cations of coccidian, especially K+, Na+, Rb+, to alter the intracellular and extracellular ion concentrations[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    751.00

    Formula

    C42H70O11

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    [H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 36.7 mg/mL (48.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.3316 mL 6.6578 mL 13.3156 mL
    5 mM 0.2663 mL 1.3316 mL 2.6631 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.66%

    References
    Cell Assay
    [2]

    For cisplatin or Salinomycin IC50 analysis in SW620 cells or Cisp-resistant SW620 cells, cells (1×104/well) are cultured in 96-well plates and treated with different chemotherapeutics (cisplatin, Salinomycin) in different concentrations for 48 h. Then 20 μL of cell counting kit-8 (CCK-8) is added into each of the 96-wells. After 4 h incubation at 37°C, the optical density (OD) values are detected at 450 nm using the scan reader. Cell growth inhibiting rates are described as cell inhibiting curves and the IC50 parameters (inhibiting concentration of 50% cells) are evaluated by Xlfit 5.2 software. For cell proliferation analysis, SW620 cells or Cisp-resistant SW620 cells (5×103/well) are also seeded in 96-well plates in serum-containing medium and treated with cisplatin (5 μM, according to the calculated IC50 values of cisplatin in SW620 cells) for 0, 12, 24, 48, 72 and 96 h. Then 20 μL cell counting kit-8 is added into each of the 96-wells. After 4-h incubation at 37°C, the coloring reactions are also quantified at 450 nm[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    Mice[3]
    Nude mice (nu/nu; 4-6 weeks of age) are used. HepG2 cells are suspended in 100 mL 1:1 serum-free DMEM and Matrigel. Mice are anesthetized with ketamine/xylazine and after surgically opening the abdomen, HepG2 cells are inoculated into the liver parenchyma and mice are monitored every 3 days for 35 days. Finally, 18 nude mice are divided into three groups that are intraperitoneally injected daily for 6 weeks: two Salinomycin-treated groups (4 mg/kg Salinomycin group, 8 mg/kg Salinomycin group) and the control group (saline water group).
    Rats[4]
    A total of 10 male rats are used in the experiment. After a routine anesthesia, the abdomen is opened. After a resuspension of high glucose medium not containing serum DMEM, and matrigel, the bladder transitional cancer cell line T24 is inoculated in the parenchyma of bladder in rats, and then the abdomen is sutured. After operation, the rats are randomized into the experiment group and the control group with five in each group. After operation, the rats in the experiment group are immediately given intraperitoneal injection of Salinomycin with a dosage of 8 mg/kg, while the rats in the control group are given intraperitoneal injection of normal saline. A close observation is paid during the drug administration period. After 15 d, the rats are sacrificed by cervical dislocation, and the complete tumor tissues are stripped to observe the tumor growth and metastasis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.3316 mL 6.6578 mL 13.3156 mL 33.2889 mL
    5 mM 0.2663 mL 1.3316 mL 2.6631 mL 6.6578 mL
    10 mM 0.1332 mL 0.6658 mL 1.3316 mL 3.3289 mL
    15 mM 0.0888 mL 0.4439 mL 0.8877 mL 2.2193 mL
    20 mM 0.0666 mL 0.3329 mL 0.6658 mL 1.6644 mL
    25 mM 0.0533 mL 0.2663 mL 0.5326 mL 1.3316 mL
    30 mM 0.0444 mL 0.2219 mL 0.4439 mL 1.1096 mL
    40 mM 0.0333 mL 0.1664 mL 0.3329 mL 0.8322 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Salinomycin
    Cat. No.:
    HY-15597
    Quantity:
    MCE Japan Authorized Agent: